← boardnext 2027-12
PLX
Protalixdistress 1/10 · well-funded / low risk$2.32-2%today-26% from 52w high
Lead: Fabry disease
Revenue
$34M
Liquidity
$41M
Runway
—
Shares 1y
+1%
Price & events
+11.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.1%
1D
+0.4%
1W
+6.9%
1M
+8.4%
3M
+11.5%
6M
+45.0%
1Y
+101.7%
2Y
+47.8%
5Y
-35.2%
All
Overview
- Market Cap
- $186.93M
- Volume
- 60.72K
- 52 Week Range
- $1.38 – $3.15
- Total Shares
- 80.57M
- Float Shares
- 77.45M
- Short %
- 4.60%
- % Held by Insiders
- 3.88%
- % Held by Institutions
- 21.33%
- RVOL
- 0.10x
- Beta
- -0.00
Pipeline stages · 1 programs
PRX-115, Methotrexate (MTX)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-12 Estimated 50% readout ~2028-01-15 | Phase 2 | PRX-115, Methotrexate (MTX) | Gout | — | recruiting |
Catalyst news & presentations · 6
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- March 2026regulatory submissionFiled (NDA/BLA)Elfabrio · EC decision on CHMP recommendation for E4W dosing regimen.SEC 8-K
- end of March 2026chmp opinionCHMP (EU)Elfabrio · EC decision on expanded dosing regimenSEC 8-K
- second half of 2025trial initiationsecondaryPhase 2PRX-115 · Initiate phase II clinical trial for PRX-115 in patients with uncontrolled gout.SEC 8-K
- 2025-10-17safety signalElfabrio · CHMP negative opinion on 2 mg/kg every 4 weeks dosing regimenSEC 8-K
- Monday, November 18, 2024, 10:30 AM – 12:30 PM ESTconferencedata presentationsecondaryPhase 1PRX-115 · Late-breaking poster presentation of Phase I PRX-115 data at ACR Convergence 2024.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-03-19HC Wainwright & Co.Buy
- 2025-11-21HC Wainwright & Co.Buy
- 2025-02-03HC Wainwright & Co.Buy
Competitors — Fabry disease
Recent news
- 2026-07-18Enterprise value to EBIT forward of PLUXEE N.V. – EURONEXT:PLX - TradingView
- 2026-07-18Pluxee (PLX) AGM 2025 Summary - Quartr
- 2026-07-14PLX ETF Profile: Dividends, Returns (XETR:PLX) - TradingView
- 2026-07-10Pope Leo XIV Price Today | PLX Live Price, Chart & Market Cap - OKX
- 2026-07-08Pluxee (PLX) Q1 2026 TU earnings summary - Quartr
- 2026-07-07Protalix BioTherapeutics (PLX) Q1 2026 Earnings: Stunning EPS Beat Drives Positive Stock Movement - Guidance Accuracy Score - dars.gov.et
- 2026-07-03PLX: Nine-month revenue up +2.7% organically, with full-year guidance confirmed despite Brazil headwinds - TradingView
- 2026-07-03PLX: Nine-month revenue up +2.7% organically; guidance for stable full-year revenue reaffirmed - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.